Bladder Cancer Immunotherapy
Building on a history of immune response to bladder cancer
Bladder cancer is the sixth most common cancer in the United States and ninth most common worldwide. While the FDA approved the Bacillus Calmette-Guérin (BCG) cancer vaccine in 1990 for the treatment of superficial, non-invasive bladder cancer, oncologists today are excited about a new class of immunotherapies called immune checkpoint inhibitors. New immunotherapies have significantly reduced the risk of recurrence for bladder cancer while also increasing the percentage of patients who see a complete response post-surgery. Dr. Matthew Galsky, of The Tisch Cancer Institute, discusses the potential to further improve outcomes for patients with this disease and answers questions from the audience. In this talk we covered how oncologists predict patient response to immunotherapies, common mutations in bladder cancer, length of treatment, and other topics. Don’t forget to submit your questions to Dr. Galsky.
Gynecologic Cancer Immunotherapy
Liver Cancer Immunotherapy
Skin Cancer and Melanoma Immunotherapy
Understanding and Overcoming Barriers to Accessing Cancer Care
Blood Cancer Immunotherapy
Breast Cancer Immunotherapy
Colorectal Cancer Immunotherapy
Kidney Cancer Immunotherapy
Lung Cancer Immunotherapy
Pancreatic Cancer Immunotherapy
Prostate Cancer Immunotherapy
Intro to CRI
Cancer Immunotherapy Basics: Harnessing Our Immune System to Fight Cancer
Clinical Trials and Cancer Immunotherapy: Accessing Promising Treatments
Patient Perspectives: Immunotherapy and Clinical Trial Experiences
Go back to event page
Hosts
Tamron Hall
Award-Winning TV Host, Journalist, Executive Producer, and Philanthropist
CRI Experts
Julie Brahmer, MD
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Andrea Cercek, MD
Memorial Sloan Kettering Cancer Center
Luis Diaz Jr., MD
Memorial Sloan Kettering Cancer Center
Peter E. Fecci, MD, PhD
Duke Cancer Center, DukeHealth, and Duke University
Lawrence Fong, MD
UCSF Helen Diller Family Comprehensive Cancer Center
Matthew D. Galsky, MD
The Tisch Cancer Institute
Sangeeta Goswami, MD, PhD
The University of Texas MD Anderson Cancer Center
Elizabeth Ann Mittendorf, MD, PhD
Dana-Farber/Harvard Cancer Center
Kunle Odunsi, MD, PhD
University of Chicago Medicine Comprehensive Cancer Center
Joseph E. Ravenell, MD
Perlmutter Cancer Center NYU Langone Health
Marcel van den Brink, MD, PhD
Memorial Sloan Kettering Cancer Center
Ana I. Velázquez Mañana, MD MSc
UCSF Helen Diller Family Comprehensive Cancer Center
Robert H. Vonderheide, MD, DPhil
University of Pennsylvania Health System
Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Jeffrey S. Weber, MD, PhD
Perlmutter Cancer Center NYU Langone Health
Theodore H. Welling, MD
Perlmutter Cancer Center NYU Langone Health
CRI ImmunoAdvocates
LaToya Bolds-Johnson, PA-C, CAQ-EM
Breast Cancer Advocate & Thriver
Stephen Estrada
Long-term Survivor of Stage 4 Colorectal Cancer
Stephanie Gangi
Breast Cancer Navigator
Sunshine Pegues
Lung Cancer Veteran
John White
Prostate Cancer Veteran
CRI Moderators
Brian Brewer
Cancer Research Institute
Sponsors
Gold
Silver
Contributor
Friend
Host Institutions
Request a clinical trials orientation appointment
Questions?
Contact
[email protected]